Genmab A/S is an international biotechnology company focused on the research, development, and commercialization of innovative antibody-based therapies. Its primary mission is to transform the treatme... Genmab A/S is an international biotechnology company focused on the research, development, and commercialization of innovative antibody-based therapies. Its primary mission is to transform the treatment landscape for cancer and other serious diseases through cutting-edge antibody technologies. Since its founding in 1999 and headquartered in Copenhagen, Genmab has established itself as a leader in the biotechnology industry by engineering and advancing novel antibody therapeutics designed to target complex diseases more effectively. The company’s portfolio spans proprietary products as well as collaborations with major pharmaceutical partners, contributing to a robust pipeline of medicines in oncology and related fields. Genmab’s antibody platforms and scientific expertise position it as a key driver of progress in the healthcare and biopharmaceutical sectors, playing a significant role in delivering next-generation therapies to patients around the world.